These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28927831)

  • 1. 'Beyond the willing & the waiting' - The role of peer-based approaches in hepatitis C diagnosis & treatment.
    Henderson C; Madden A; Kelsall J
    Int J Drug Policy; 2017 Dec; 50():111-115. PubMed ID: 28927831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
    Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
    Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tensions in relation: How peer support is experienced and received in a hepatitis C treatment intervention.
    Bonnington O; Harris M
    Int J Drug Policy; 2017 Sep; 47():221-229. PubMed ID: 28606391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection.
    Crawford S; Bath N
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S75-9. PubMed ID: 23884070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
    Arain A; Robaeys G
    World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will peer-based interventions improve hepatitis C virus treatment uptake among young people who inject drugs?
    Jacob J; Ti L; Knight R
    Can J Public Health; 2021 Jun; 112(3):460-463. PubMed ID: 32936434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterising the policy influence of peer-based drug user organisations in the context of hepatitis C elimination.
    Brown G; Perry GE; Byrne J; Crawford S; Henderson C; Madden A; Lobo R; Reeders D
    Int J Drug Policy; 2019 Oct; 72():24-32. PubMed ID: 31176595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.
    Zeremski M; Zibbell JE; Martinez AD; Kritz S; Smith BD; Talal AH
    World J Gastroenterol; 2013 Nov; 19(44):7846-51. PubMed ID: 24307778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Values and preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan.
    Martínez-Pérez GZ; Nikitin DS; Bessonova A; Fajardo E; Bessonov S; Shilton S
    BMC Infect Dis; 2021 Jun; 21(1):609. PubMed ID: 34171990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
    Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S129-37. PubMed ID: 23884061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol.
    Swan D; Cullen W; Macias J; Oprea C; Story A; Surey J; Vickerman P; Lambert JS
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):303-314. PubMed ID: 29300496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
    Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C;
    Int J Drug Policy; 2019 Oct; 72():1-10. PubMed ID: 31345644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research.
    Jones L; Atkinson A; Bates G; McCoy E; Porcellato L; Beynon C; McVeigh J; Bellis MA
    Int J Drug Policy; 2014 Mar; 25(2):204-11. PubMed ID: 24332457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.
    Aspinall EJ; Weir A; Sacks-Davis R; Spelman T; Grebely J; Higgs P; Hutchinson SJ; Hellard ME
    Int J Drug Policy; 2014 Jan; 25(1):179-82. PubMed ID: 24315504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia.
    Butler K; Day C; Sutherland R; van Buskirk J; Breen C; Burns L; Larney S
    Int J Drug Policy; 2017 Sep; 47():102-106. PubMed ID: 28789820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
    Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
    Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.